(Q44517908)

English

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study

scientific article published in July 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Flavia Tosi

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Michele Muggeo

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Elisabetta Brun

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Giovanna Spiazzi

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Laura Perobelli

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Elisabetta Zanolin

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Mario Gori

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Alessandro Coppini

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Paolo Moghetti

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

862-867

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Forum One: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

The beta cell in NIDDM: giving light to the blind

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900101-X

7 January 2021

Identifiers

10.1016/S0026-0495(03)00101-X

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44517908&oldid=2026608112"